JOP20200135A1 - مركبات psma الترابطية للتصوير والعلاج الإشعاعي الداخلي - Google Patents

مركبات psma الترابطية للتصوير والعلاج الإشعاعي الداخلي

Info

Publication number
JOP20200135A1
JOP20200135A1 JOP/2020/0135A JOP20200135A JOP20200135A1 JO P20200135 A1 JOP20200135 A1 JO P20200135A1 JO P20200135 A JOP20200135 A JO P20200135A JO P20200135 A1 JOP20200135 A1 JO P20200135A1
Authority
JO
Jordan
Prior art keywords
endoradiotherapy
imaging
psma
psma ligands
compounds
Prior art date
Application number
JOP/2020/0135A
Other languages
English (en)
Inventor
Alexander Schmidt
Mara Parzinger
Hans-Jurgen Wester
Original Assignee
Univ Muenchen Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Muenchen Tech filed Critical Univ Muenchen Tech
Publication of JOP20200135A1 publication Critical patent/JOP20200135A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nuclear Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

يتعلق الكشف الحالي بالتصوير والعلاج الإشعاعي الداخلي للأمراض شاملة مولد ضد لغشاء انتقائي للبروستاتا (PSMA). تم تقديم مركبات والتي تقوم بربط أو تثبيط PSMA وعلاوة على ذلك تحمل شق واحد على الأقل القابلة للتعديل إلى التعليم الإشعاعي. تم أيضا تقديم الاستخدامات الطبية لهذه المركبات.
JOP/2020/0135A 2017-12-11 2018-12-11 مركبات psma الترابطية للتصوير والعلاج الإشعاعي الداخلي JOP20200135A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17206510 2017-12-11
PCT/EP2018/084399 WO2019115547A1 (en) 2017-12-11 2018-12-11 Psma ligands for imaging and endoradiotherapy

Publications (1)

Publication Number Publication Date
JOP20200135A1 true JOP20200135A1 (ar) 2020-06-02

Family

ID=60654872

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2020/0135A JOP20200135A1 (ar) 2017-12-11 2018-12-11 مركبات psma الترابطية للتصوير والعلاج الإشعاعي الداخلي

Country Status (30)

Country Link
US (2) US11497819B2 (ar)
EP (2) EP3723815B1 (ar)
JP (2) JP7317375B2 (ar)
KR (1) KR20200097690A (ar)
CN (2) CN116617421A (ar)
AU (1) AU2018382479A1 (ar)
BR (1) BR112020011727A2 (ar)
CA (1) CA3078104A1 (ar)
CL (1) CL2020001542A1 (ar)
CR (1) CR20200241A (ar)
CU (1) CU24677B1 (ar)
DK (1) DK3723815T3 (ar)
EC (1) ECSP20029142A (ar)
ES (1) ES2914832T3 (ar)
HR (1) HRP20220764T1 (ar)
HU (1) HUE059083T2 (ar)
IL (1) IL274072A (ar)
JO (1) JOP20200135A1 (ar)
LT (1) LT3723815T (ar)
MX (2) MX2020005430A (ar)
PE (1) PE20210456A1 (ar)
PL (1) PL3723815T3 (ar)
PT (1) PT3723815T (ar)
RS (1) RS63279B1 (ar)
SG (1) SG11202002965WA (ar)
SI (1) SI3723815T1 (ar)
TN (1) TN2020000072A1 (ar)
UA (1) UA126413C2 (ar)
WO (1) WO2019115547A1 (ar)
ZA (1) ZA202003472B (ar)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200135A1 (ar) 2017-12-11 2020-06-02 Univ Muenchen Tech مركبات psma الترابطية للتصوير والعلاج الإشعاعي الداخلي
AU2020296488A1 (en) 2019-06-21 2022-01-20 Provincial Health Services Authority Radiolabeled compounds targeting the prostate-specific membrane antigen
CN112321673B (zh) * 2020-11-04 2022-09-20 北京市肿瘤防治研究所 一种前列腺特异性膜抗原靶向抑制剂及应用和探针
CN113354707A (zh) * 2021-06-07 2021-09-07 苏州思萃同位素技术研究所有限公司 一种针对前列腺癌的三功能诊疗一体化药物前体的合成方法及其产品
WO2023173074A2 (en) * 2022-03-10 2023-09-14 The Research Foundation For The State University Of New York Immunostimulant-cytotoxic conjugate composition and methods for cancer treatment
CN115010629B (zh) * 2022-06-07 2024-02-23 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其核素标记物及制法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1888581A2 (en) 2005-05-16 2008-02-20 Gilead Sciences, Inc. Hiv-integrase inhibitor compounds
CN113563262A (zh) * 2008-08-01 2021-10-29 约翰.霍普金斯大学 Psma-结合剂及其用途
WO2010135431A2 (en) * 2009-05-19 2010-11-25 The Regents Of The University Of California Compositions, devices, and methods related to prostate-specific membrane antigen
LT4095130T (lt) * 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
US10683272B2 (en) 2014-05-06 2020-06-16 The Johns Hopkins University Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy
US10688200B2 (en) 2015-12-31 2020-06-23 Five Eleven Pharma Inc. Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
KR20230147751A (ko) * 2016-03-22 2023-10-23 더 존스 홉킨스 유니버시티 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
JOP20200135A1 (ar) 2017-12-11 2020-06-02 Univ Muenchen Tech مركبات psma الترابطية للتصوير والعلاج الإشعاعي الداخلي
TW201930265A (zh) 2017-12-11 2019-08-01 西班牙商阿爾米雷爾有限公司 作為acc抑制劑的吡咯衍生物
US11299472B2 (en) 2017-12-11 2022-04-12 Helsinn Healthcare Sa Fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2- trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, methods of preparation, and uses thereof

Also Published As

Publication number Publication date
JP7317375B2 (ja) 2023-07-31
CN111182927A (zh) 2020-05-19
RS63279B1 (sr) 2022-06-30
CN111182927B (zh) 2023-07-21
HRP20220764T1 (hr) 2022-09-16
ECSP20029142A (es) 2020-09-30
JP2021505532A (ja) 2021-02-18
SG11202002965WA (en) 2020-04-29
CU20200052A7 (es) 2021-03-11
TN2020000072A1 (en) 2022-01-06
HUE059083T2 (hu) 2022-10-28
EP4008359A1 (en) 2022-06-08
US11497819B2 (en) 2022-11-15
PE20210456A1 (es) 2021-03-08
RU2020116158A (ru) 2022-01-13
EP3723815B1 (en) 2022-04-20
SI3723815T1 (sl) 2022-07-29
CR20200241A (es) 2020-09-21
AU2018382479A1 (en) 2020-04-16
CN116617421A (zh) 2023-08-22
CU24677B1 (es) 2023-09-07
DK3723815T3 (da) 2022-07-11
CL2020001542A1 (es) 2020-10-02
EP3723815A1 (en) 2020-10-21
MX2023005053A (es) 2023-05-17
JP2023139063A (ja) 2023-10-03
BR112020011727A2 (pt) 2020-11-17
US20230122957A1 (en) 2023-04-20
ZA202003472B (en) 2022-06-29
ES2914832T3 (es) 2022-06-16
KR20200097690A (ko) 2020-08-19
PL3723815T3 (pl) 2022-07-18
MX2020005430A (es) 2020-08-27
LT3723815T (lt) 2022-07-25
PT3723815T (pt) 2022-05-30
UA126413C2 (uk) 2022-09-28
IL274072A (en) 2020-06-30
US20200297876A1 (en) 2020-09-24
CA3078104A1 (en) 2019-06-20
WO2019115547A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
MX2023005053A (es) Ligandos de psma para la formacion de imagenes y endorradioterapia.
ZA201906832B (en) Novel psma-binding agents and uses thereof
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
MX2017016611A (es) Moduladores de tgr5 y metodos de uso de los mismos.
EA201892430A1 (ru) Синтез индазолов
UY36757A (es) Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
EA201691323A1 (ru) Анти-vista антитела и фрагменты
TR201909093T4 (tr) Hidroksi içeren FXR (NR1H4) modüle edici bileşikleri.
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
EA201691487A1 (ru) Антитела человека к pd-l1
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
MA34057B1 (ar) تركيبات وأساليب لتشخيص وعلاج ورم
EA201791050A1 (ru) Конъюгаты антител и лекарственных средств
PH12020551443A1 (en) Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
WO2015054642A3 (en) Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy
EP3700917A4 (en) NEW RADIOMETAL BINDING COMPOUNDS FOR THE DIAGNOSIS OR TREATMENT OF CANCER EXPRESSING A PROSTATE-SPECIFIC MEMBRANARY ANTIGEN
EA201692100A1 (ru) Новые антитела против rnf43 и способы их применения
EA201691541A1 (ru) Новые анти-baff антитела
MA38986B1 (fr) Inhibiteurs marqués de l'antigène membranaire spécifique de la prostate (psma), leur utilisation comme agents d'imagerie et agents pharmaceutiques pour le traitement du cancer de la prostate
EA201691141A1 (ru) Соединения против ccr6
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
GEP20207106B (en) 18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer
EA201992318A1 (ru) Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
BR112014025560A2 (pt) anticorpos anti-pdgf-c
CY1123406T1 (el) Παραγωγο τριαζολοπυραζινονης χρησιμο ως ενας ανθρωπινος pde1 αναστολεας